Core Insights - The 2025 Future Medical and Pharmaceutical Top 100 Exhibition (VBEF) was held in Suzhou, showcasing advancements in medical technology, with Shenzhen Beixin Life Technology Co., Ltd. recognized in the "Top 100 Chinese Innovative Medical Devices and Intelligent Manufacturing" list [1] - Beixin Life's core product, the Intravascular Ultrasound (IVUS) system, won the "Best Intelligent Medical Device Technology Innovation Product" award, marking a significant achievement in the cardiovascular precision intervention field [1][2] - The company has successfully broken the long-standing dominance of imported products in China's cardiovascular precision diagnosis market, completing this transition in nine years [1] Product and Technology Highlights - The IVUS system features a 60MHz imaging resolution, high retraction speed, and intelligent operation, establishing a strong position in the domestic market [2] - It is the first domestically developed IVUS system approved under the EU MDR, successfully entering international markets [2] - The FFR (Fractional Flow Reserve) system, another core product, is recognized as the first domestically approved gold standard FFR system, showcasing Beixin Life's technological leadership [2] Innovation and Development - Beixin Life has established four core technology platforms: micro-nano device research and packaging, interventional catheter research and processes, high-performance medical hardware development, and high-performance signal and image algorithms [2][3] - The company has launched 11 commercialized products based on these platforms, obtaining over 20 Class III medical device registration certificates, and serving more than 1,000 hospitals and 150,000 patients globally [2] - The IVUS system incorporates advanced features such as the inSmartVision platform for automatic image analysis and the EasyGO function for angiography registration, enhancing clinical efficiency and reducing procedure time [3] Future Aspirations - Beixin Life aims to continue its mission of improving life and health through innovation and quality, aspiring to become a world-class medical technology enterprise with lasting influence [3] - The recognition from the awards and the inclusion in the top 100 list serve as validation of the company's technological innovations and clinical value, motivating further advancements in the cardiovascular precision intervention sector [3]

Core Insights - North Chip Life Technology Co., Ltd. has focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases since its establishment in 2015 [1] - The company has broken the monopoly of overseas giants in the field of cardiovascular precision intervention and has filled multiple domestic gaps [1] - North Chip Life has received over ten Class III medical device registration certificates both domestically and internationally, with 185 authorized patents as of June 30, 2025, including 86 invention patents [1] Product Highlights - The company's intravascular ultrasound (IVUS) system is the first domestically approved high-definition (60 MHz) IVUS product in China and the first to be approved for overseas sales (EU MDR) [1] - The core product, the fractional flow reserve (FFR) measurement system, is also the first domestically approved FFR product in China and the first to be approved for overseas sales (EU MDR), recognized as "internationally leading and domestically pioneering" by the National Medical Products Administration [1] - These products have significantly improved the precision and effectiveness of cardiovascular disease diagnosis and treatment [2] Market Reach and Recognition - North Chip Life's cardiovascular precision intervention solutions have been implemented in over 1,500 hospitals across more than 50 countries, benefiting over 150,000 patients globally [2] - The FFR system has been recognized by Boston Consulting Group as a representative product of China's medical device innovation 3.0 [2] - The 2024 Medical Device Industry Innovation Index recognized North Chip Life as one of the "Top 100 Innovative Enterprises" and "Outstanding Enterprises in Overseas Expansion" [2] Future Vision - The company aims to become a world-class medical technology enterprise with a lasting impact, continuing to invest in research and development to provide more quality diagnostic options for global cardiovascular disease patients [3]